• Optimizing Immunoassays with c-Myc tag Peptide: Protocols &

  2026-06-04

  The c-Myc tag Peptide empowers researchers with reliable displacement of c-Myc-tagged fusion proteins and robust anti-c-Myc antibody binding inhibition in high-specificity immunoassays. Explore advanced workflow enhancements, troubleshooting guidance, and actionable protocol parameters that maximize reproducibility in cell signaling and cancer research assays.

• Cyclic Pifithrin-α Hydrobromide: Beyond p53 Inhibition in Ra

  2026-06-03

  Explore how Cyclic Pifithrin-α hydrobromide, a potent p53 inhibitor, is transforming apoptosis research and radioprotection strategies. This article uniquely examines its mechanistic versatility and cross-domain utility, bridging cancer biology and neuroinflammatory disease insights.

• Screening FDA-Approved Drugs for MERS-CoV Inhibition: Lopina

  2026-06-03

  de Wilde et al. systematically screened 348 FDA-approved compounds and identified four small molecules, including Lopinavir (ABT-378), that inhibit MERS-CoV replication in cell culture. The study provides a framework for rapid repurposing of antiviral agents in emerging coronavirus outbreaks, highlighting both opportunities and limitations in translating in vitro results to clinical settings.

• Cy3 Goat Anti-Human IgG (H+L) Antibody: Benchmarks & Protoco

  2026-06-02

  The Cy3 Goat Anti-Human IgG (H+L) Antibody enables sensitive, specific detection of human immunoglobulins across immunoassays. This Cy3 conjugated secondary antibody, produced by APExBIO, supports robust signal amplification and reproducibility. Benchmarks and integration parameters are detailed for translational and diagnostic workflows.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Receptor B

  2026-06-02

  Oliveira et al. (2025) reveal that naturally occurring angiotensin peptides, particularly truncated variants, can enhance the binding of the SARS-CoV-2 spike protein to cell surface receptors, most notably AXL. This finding suggests a novel molecular interface between the renin-angiotensin system and COVID-19 pathogenesis, highlighting potential new therapeutic targets and considerations for cardiovascular research.

• SELENOK Regulates Microglial CD36 Palmitoylation and Aβ Clea

  2026-06-01

  The referenced study demonstrates that SELENOK, a selenoprotein, is crucial for promoting microglial phagocytosis of amyloid-beta via regulation of CD36 palmitoylation. This mechanism provides new insight into Alzheimer’s disease pathogenesis and suggests selenium-based interventions as potential therapeutic strategies.

• Cyanine 3-dCTP: Enabling Precision in DNA Fluorescent Labeli

  2026-06-01

  Discover how Cy3-dCTP empowers high-efficiency, site-specific fluorescent labeling of DNA and cDNA. This article explores unique mechanistic insights, advanced assay design, and cutting-edge applications that set Cyanine 3-deoxycytidine triphosphate apart for innovative genomics workflows.

• Beyond Transfection: Strategic Deployment of ARCA EGFP mRNA

  2026-05-31

  Explore how ARCA EGFP mRNA (5-moUTP) advances translational research by bridging mechanistic innovation, experimental rigor, and workflow reproducibility in mammalian cell assays. This article synthesizes cutting-edge evidence on polyadenylated mRNA optimization, immune evasion, and storage parameters, offering actionable guidance for next-generation reporter deployment.

• CHIR-99021: Mechanistic Precision in Translational Organoid

  2026-05-30

  Explore how CHIR-99021 (CT99021), a highly selective GSK-3 inhibitor from APExBIO, is redefining the boundaries of translational organoid research. This article blends mechanistic insight into Wnt/β-catenin and TGF-β/Nodal signaling with actionable strategic guidance—contextualized through the latest breakthroughs in limb organoid modeling and pluripotency maintenance. Readers gain evidence-based parameters, competitive intelligence, and forward-looking perspective on stem cell differentiation and spatial morphogenesis.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guidance for Label

  2026-05-29

  Cy3 NHS ester (non-sulfonated) provides a robust solution for fluorescent labeling of proteins, peptides, and oligonucleotides targeting amino groups. It is optimal when high signal intensity and compatibility with organic co-solvents are required, but less suitable for labeling delicate proteins that are sensitive to non-aqueous conditions.

• Trichostatin A (TSA): Advanced Epigenetic Workflows in Cance

  2026-05-29

  Trichostatin A (TSA) empowers researchers to dissect epigenetic regulation in cancer, delivering reliable cell cycle arrest and antiproliferative effects across diverse experimental models. This guide translates current literature and reference breakthroughs into actionable protocols, troubleshooting strategies, and future-focused insights for oncology and cell differentiation studies.

• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-05-28

  This study demonstrates that activation of PPARγ directs macrophage polarization from a proinflammatory M1 state toward an anti-inflammatory M2 phenotype, ameliorating symptoms in a dextran sulfate sodium-induced mouse model of inflammatory bowel disease. Findings clarify the mechanistic role of the STAT-1/STAT-6 pathway, providing a foundation for immunometabolic research targeting macrophage-driven inflammation.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Use and Q

  2026-05-28

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables specific, sensitive detection of goat IgG in immunofluorescence-based workflows such as ICC, IHC, flow cytometry, and ELISA. It should only be used with goat primary antibodies and is not appropriate for detection of other species’ primaries or for applications outside validated immunodetection workflows. Proper storage, handling, and protocol adherence are essential to maximize signal and minimize background.

• Doxorubicin for Cancer Research: Protocols, Workflows & Tips

  2026-05-27

  Doxorubicin (Adriamycin) is a gold-standard chemotherapeutic agent for modeling DNA damage, apoptosis, and synergistic drug responses in solid tumor and hematologic malignancy research. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights to help you maximize experimental rigor and translational relevance.

• SCH772984: Potent ERK1/2 Inhibitor for Oncogenic MAPK Resear

  2026-05-27

  SCH772984 is a selective ATP-competitive ERK1/2 inhibitor with nanomolar potency, enabling precise MAPK/ERK pathway inhibition in BRAF, NRAS, and KRAS mutant tumor models. Its high selectivity and robust in vivo efficacy, particularly in combination therapy, make it a cornerstone reagent for translational cancer research.

8094 records 10/540 page Previous Next First page 上5页 678910 下5页 Last page